Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

• Published in: European journal of nuclear medicine and molecular imaging 2014-10, Vol.41 (10), p.1831-1844
• Main Authors: Kong, G., Thompson, M., Collins, M., Herschtal, A., Hofman, M. S., Johnston, V., Eu, P., Michael, M., Hicks, Rodney J.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antineoplastic Agents - therapeutic use; Cardiology; Chemoradiotherapy - methods; Chemotherapy; Endocrine system; Female; Humans; Imaging; Male; Medicine; Medicine & Public Health; Middle Aged; Neuroendocrine Tumors - diagnosis; Neuroendocrine Tumors - therapy; Neurons; Nuclear Medicine; Octreotide - analogs & derivatives; Octreotide - therapeutic use; Oncology; Original; Original Article; Orthopedics; Patients; Peptides; Radiology; Radiopharmaceuticals - therapeutic use; Receptors, Somatostatin - metabolism; Survival Analysis; Treatment Outcome; Tumors
• ISSN: 1619-7070; 1619-7089
• DOI: 10.1007/s00259-014-2788-5

Purpose To review the response and outcomes of 177 Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. Methods A total of 68 patients (39 men; 17 – 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had concomitant 5-FU radiosensitizing infusional chemotherapy. Factors predicting overall survival were assessed using the log-rank test and Cox proportional hazards regression. Results Of those treated for uncontrolled symptoms, 70 % received benefit maintained for at least 6 months after treatment. Among patients with progressive disease 68 % showed stabilization or regression on CT, 67 % on molecular imaging and 56 % biochemically up to 12 months after treatment; 32 patients died. Overall survival rates at 2 and 5 year were 72.1 % and 52.1 %, respectively. Median overall survival was not estimable at a median follow-up of 60 months (range 5 – 86 months). Nonpancreatic primary sites, dominant liver metastases, lesion size 5 cm) appeared to have lower objective response rates and may need a more aggressive treatment approach.